Cadila Healthcare Ltd - PowerPoint PPT Presentation


PPT – Cadila Healthcare Ltd PowerPoint presentation | free to download - id: 56ebc-ZDc1Z


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation

Cadila Healthcare Ltd


Zydus Cadila- One of India's leading. integrated pharma companies ... Day 1 launches of Meloxicam, Simvastatin and Carvedilol) ... – PowerPoint PPT presentation

Number of Views:1770
Avg rating:3.0/5.0
Slides: 21
Provided by: leena
Learn more at:


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Cadila Healthcare Ltd

Cadila Healthcare Ltd
Investor Presentation May 2008
Zydus Cadila- One of Indias leading integrated
pharma companies
  • Ranked 4th in Indian formulations market. (as per
    ORG IMS MAT Mar-08).
  • Formulations exports grew by 70 in last four
    years on the back of rapid growth in developed /
    semi regulated generics markets of US, France and
  • Focusing on Research Development spending 7
    of the revenues on RD every year.
  • FY
    07-08 FY 06-07 Gr
  • Consol. Revenues 577 mn 409
    mn 27 Consol. Operating PAT 63 mn
    46 mn 23
  • Market Capitalisation of 1 bn.

Core Business Areas and their Revenue Break-up
Revenue break-up by segment
Revenue break-up by region
Break-up of Revenue (FY 2007-08)
State of the art facilities and infrastructure
  • Formulations four manufacturing plants
  • Moraiya (Gujarat)
  • Largest integrated facility in Asia facilities
    for producing almost all types of dosage forms
  • Baddi (Himachal Pradesh) for catering to
    domestic market
  • Goa for catering to both domestic and non
    regulated markets
  • Sikkim for catering to domestic market
  • Amongst few in India to make lyophilised
    products, vaccines, aerosols, hormones and
    cytotoxic products,
  • Only producer of transderamal patches and
    suppositories in India
  • APIs and Fine Chemicals three plants
  • Ankleshwar and Dabhasa (Gujarat) US FDA
    approved multi purpose plants
  • Fully dedicated fine chemicals facility at
    Ahmedabad (Gujarat)
  • Contract Manufacturing
  • Mumbai (Zydus Nycomed JV) dedicated facility
    for Pantoprazole intermediates
  • Goa dedicated facility for manufacturing
    Agiolax for Madaus AG
  • Ahmedabad - cytotoxic injectibles production
    facility for Zydus Hospira JV
  • Ahmedabad - cytotoxic facility for NDDS product
    for Zydus BSV JV

Overall strategy
  • Continued focus on domestic market
  • Grow rapidly in key regulated global generics
    markets- US, Europe Latin America
  • Leverage strengths through contract manufacturing
  • Focus on innovation- RD

India Formulations - strategy
  • Maintain overall position and market share
  • Focus on fast growing chronic/ lifestyle segments
  • Continued new product introductions
  • In-licensing arrangements- Schering AG,
    Boehringer Ingelheim, Meda Pharma etc.
  • Market expansion explore new therapeutic areas
    and geographies
  • Marketing excellence

Portfolio shift to life style and chronic
Achievements in Indian market
  • Zydus Cadila ranks 4th with Rs 11.5bn sales.
    (Source ORG IMS MAT Mar-08)
  • 16 Zydus brands feature amongst the top 300
    brands. (as per ORG IMS MAT Mar-08)
  • Creation of a special field force to tap growth
    potential of rural market, considered to be the
    next growth driver for formulations business in
    India, has showed encouraging results, and has
    prompted us to further expand field force in
    rural areas.
  • In all, launched gt35 new products and gt25 line
    extensions in FY 07-08, of which 10 were 1st in
  • With acquisition of Liva Healthcare, we entered
    Rs. 15 bn dermatology market, growing at 14. We
    introduced range of cosmetology products in Liva
    with special field force for the same.
  • We now plan to strengthen our position in
    neutraceuticals, orthopedic and diagnostics
    segment by adding special field forces for these

Zydus Rank
Therapeutic Area

Female Healthcare
Segment ranking and Market Share refer to
participated market. SourceORG-IMS MAT Mar-08
Prioritized Generics Markets
International business- two fold focus
  • Developed generics markets
  • US- the largest generic market in the world
  • Zydus Pharmaceuticals USA Inc.
  • Europe- Zydus France SAS
  • Planning to enter Spain Italy
  • Japan- Zydus Pharmaceuticals Inc.
  • Nippon Universal Pharmaceuticals Ltd.
  • Emerging markets
  • CIS - Russia , Ukraine
  • Asia Pacific- Sri Lanka, Vietnam, Myanmar
  • Africa, Middle East
  • Brazil, South America

International sales projections
Formulations-emerging markets
Formulations- developed markets
APIs/intermediates- exports
2007-08 US 217 mn
2010E US 450 mn
Organic sales projections, except formulations
in emerging markets, which includes Nikkho do
Brazil acquisition
US marketing plan and achievements so far
  • Marketing and distribution through Mallinckrodt,
    which is 7th largest generic player in US, under
    the joint label ZyPharma.
  • Also doing direct marketing to select customers
    under label ZyGenerics.
  • Launched 15 products so far (incl. Day 1 launches
    of Meloxicam, Simvastatin and Carvedilol). Plan
    to launch 8-10 products every year.
  • Response has been excellent with market share gt
    10 in over half of the products.
  • With sales gt 63 Mio. (FY 07-08), and high
    growth rate which is expected to continue for
    next couple of years, Zydus is now rated a top
    tier generics company among peers in US.

Robust regulatory pipeline
  • ANDAs approved represent gt 20 bn market size
    (of resp. branded product)
  • Almost half of the products envisage own API.
  • Plan to file 15-20 ANDAs every year for next 2-3

France key initiatives so far
  • Complete focus on Pure
  • Generics
  • Attained gt2 share in the participated generics
    market, within 3 years of start of generics biz.
    Rated fastest growing generic company in France
    (Source IMS)

  • Relationship with
  • pharmacists
  • Building special relationship with pharmacists
  • Supporting a health awareness program for the
    Zydus club of pharmacists
  • Launch of generics
  • Launched gt100 generic presentations so far.
  • Plan to boost the basket with launch of 12-15
    products every year for next 2-3 years.

Leveraging Indias lower cost
Generics to drive our French business
Emerging Global Markets
  • Continuous Growth Momentum
  • Presence in over 25 semi / non regulated emerging
  • Amongst top 3 Indian pharma cos. in Sri Lanka,
    Myanmar, Philippines, Uganda and Sudan.
  • Focusing and developing base in rapidly growing
    markets of Brazil, Russia and Japan.
  • Exports to these markets grew by gt50 in last 3
    years and crossed Rs.2 bn mark in FY07-08.
  • Brazil
  • Started operations in 2005-06 with entry in pure
    generics market thru own subsidiary.
  • Filed 37 generics dossiers and received 13
    approvals so far. All have been launched.
  • Recent acquisition of Nikkho do Brazil Ltda.
    provides entry into fast growing, profitable
    and sustainable branded generics segment.
  • A profit-making co., Nikkho has a mfg. facility
    and strong marketing and distribution network in
  • Present basket of 14 brands to be expanded with
    launch of more brands from 50 registered
    unlaunched brands.
  • Japan
  • Opened up a new subsidiary in Japan - Zydus
    Pharma Inc. to kick start operations.
  • The subsidiary will market APIs and formulations
    in Japanese market, and start product
    registration process in 2008.
  • Operations to commercialise by 2010.
  • Recently acquired Nippon Universal
    Pharmaceuticals Ltd., which has got countrywide
    reach to more than 4000 hospital and clinics in
  • The acquisition provides critical access to a
    ready mfg. and marketing base as well as a strong
    distribution network.

Consumer Products building strong brands
  • Presence in low calorie sweetener and skincare
    products business in India since more than 15
  • Sugar Free group
  • The healthier alternative to sugar, Sugar Free is
    a market leader in India with market share of
    gt75 (Source AC Nielsen).
  • Growing at CAGR of over 20 for last 3 years, the
    brand crossed Rs. 650 mn sales mark in FY 07-08.
  • Everyuth range of skincare products have also
    been growing at CAGR of 20 for last 3 years.
  • To complement Sugar Free in life style segment,
    acquired 62 stake in Mar-06 in Carnation
    Nutra-Analogue Foods Ltd., the manufacturers of
  • Indias largest selling margarine, Nutralite is
    free from cholesterol and a healthier substitute
    for butter.
  • After acquisition, revamped the brand Nutralite,
    with change in packs, packing style, special
    promotional campaign and shift of focus from bulk
    to retail segment, which yielded result in the
    very first year. It crossed sales Rs. 550 mn with
    32 growth and registered positive bottmline in
    FY 07-08.

Contract manufacturing - exciting prospects
  • With world class state of the art manufacturing
    facilities, dedicated IPR team enabling rapidity
    in site transfers and competency in development
    projects, Zydus is uniquely positioned on
    Contract mfg. front.
  • Zydus Nycomed JV - benchmark in contract
  • State of the art manufacturing facility set up as
    an EOU near Mumbai.
  • Supplying gt60 of the global requirements for two
    key starting materials of Pantoprazole to its
    worldwide patent holder, Nycomed.
  • Plan to expand scope of the JV by transferring
    current API production of Nycomed from its
    existing facilities to the JVs plant over a
    period of four years.
  • Zydus Hospira - JV for oncology injectables
  • JV for mfg. and marketing generic cytotoxic
    injectable products worldwide
  • Set up cytotoxic facility located in an SEZ near
  • Commercial production expected to start in FY
  • Full capacity utilisation in FY 10-11.
  • 29 other contracts with innovator and generic
    MNCs signed so far with peak revenue potential of
    US 43 Mio.

Research Focus
Scientific Talent Pool 800
  • Zydus Research Centre (ZRC)
  • Located in Ahmedabad
  • Focused on NME Research NDDS
  • Pharmaceutical Technology Centre (PTC)
  • 2 centers one located in Ahmedabad, another in
  • Focused on Finished Dosage Form Development

RD Spends FY 07-08
  • API Process Research
  • Located in Ankleshwar/Ahmedabad
  • Focused on Process Development

Rs. 1,588 Mio. ( 39 Mio.) (7
of revenues)
Zydus Research Center - investing for the future
  • NME Research, Biologicals (Biogenerics) NDDS.
  • Therapeutic Area Diabetes, Dyslipidemia,
    Obesity, Inflammation.
  • Infrastructure for target identification to
    pre-clinical research / early clinical
  • Lead lipid lowering drug candidate ZYH1 and
    anti-inflammatory pain management compound ZYI1
    are in Phase II clinical trials.
  • ZYH2, the novel agent for treating diabetes and
    ZYO1, the candidate for treating obesity and
    related disorders are undergoing Phase I clinical
  • Recently filed 5th IND ZYH7, a novel drug
    candidate for treating dyslipidemia and metabolic
  • Multiple candidates under preclinical stage.

NME Pipeline
IND Filing
Phase 1
Phase 2
Phase 3
Pre Clinical
PTC The Single Window for Global Dossiers
PTC Scientific Team
  • Product Development team of 325 scientists
  • In-house Regulatory, IPR Packaging development
  • Infrastructure
  • Development labs
  • Pilot Plant
  • Analytical Support
  • Stability studies
  • Pharmacokinetics
  • Recently added facilities to develop parenteral
    products both liquid and lyophilised,
    transdermal drug delivery systems and respiratory
    dosage forms

Financial Highlights

Our vision
Zydus shall be a leading global healthcare
provider with a robust product pipeline and sales
of over 1 bn by 2010 we shall achieve sales of
over 3 bn by 2015 and be a research-based
pharmaceutical company by 2020.
Thank You.
No part of this presentation may be reproduced,
quoted or circulated without prior written
approval from Cadila Healthcare Ltd.. This
presentation may include certain forward looking
statements , based on current expectations,
within the meaning of applicable laws and
regulations. Actual results may differ and the
company does not guarantee realization of these
statements.The Company also disclaims any
obligation to revise any forward-looking
statements . The viewers may use their own
judgement and are advised to make their own
calculations before deciding on any matter based
on the information given herein